Acute Coronary Syndrome, Diabetes Mellitus
Conditions
Keywords
platelet aggregation, acute coronary syndrome, diabetes
Brief summary
Diabetes is an important risk factor of coronary atherosclerosis, and it's well known that platelets of diabetic patients are hyper reactive and so resistant to common antithrombotic therapy. Moreover, in diabetic patients platelets are characterized by high turnover that is responsible of lack of protection by cardioaspirin at common dosage. The aim of our study is to asses the efficacy of different doses of aspirin in diabetic patients with acute coronary syndrome.
Interventions
DRUGaspirin 100 mg bis in die
Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
DRUGaspririn 200 mg once daily
Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
DRUGaspirin 100 mg once daily
Patient will be randomized and after 10 days and 30 days we will measure platelets aggregation.
Sponsors
Federico II University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
40 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
* Diabetic patients with acute coronary syndrome after 24 hours from the coronarography
Exclusion criteria
* patients with a family or personal history of bleeding or thrombophilic disorders; * platelet count \>600000/mmc or \<150000/mmc * hematocrit \>50% or \<25% * creatinine clearance \<30 mL/min
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Effects of different doses of aspirin on platelet aggregation | 1 month | Valuation of different doses of aspirin once or twice daily on platelet aggregation after 10 day and 30 day from the acute coronary syndrome |
Secondary
| Measure | Time frame |
|---|---|
| Valuation of RAC1 levels in platelets | 1 month |
Countries
Italy
Outcome results
None listed